Immunogenic formulation of OSPC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens

摘要

A novel approach to Borrelia vaccine formulation taking into account serological, genotypic and epidemiological information by which OspC proteins from different strains of B burgdorferi are grouped together. OspC antigens are chosen in order to constitute a representative sample of such groupings, so that the resulting vaccine provides the greatest cross-protectivity with the fewest number of antigens.